Jan 22, 2025 17:18 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company

TOKYO, Jan 22, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2025 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s ninth inclusion on the list. Ranked 35th, Eisai is the highest ranking among global pharmaceutical companies. Eisai was also the highest ranking among the 3 Japanese companies listed in the Global 100 (please visit here(New Window) for the Global 100 ranking).

The Global 100 evaluates the sustainability of more than 8,300 of the world’s major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year. The Global 100 is based on up to 25 key performance indicators covering ESG initiatives, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai was highly evaluated, particularly in indicators for reflecting the sustainability targets in executive compensation, enhancing measures to maintain employee health, employee retention rate, and environmental conservation initiatives.

Eisai’s corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Based on this human health care (hhc) corporate concept, Eisai is striving to sustainably enhance corporate value by strengthening its sustainability initiatives and increasing non-financial value.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
January 15 2025 09:03 JST
 
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
January 07 2025 08:14 JST
 
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
December 23 2024 16:22 JST
 
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
December 11 2024 13:45 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
December 05 2024 10:22 JST
 
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
November 28 2024 15:26 JST
 
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
November 26 2024 14:50 JST
 
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
November 20 2024 10:51 JST
 
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
November 20 2024 09:24 JST
 
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
November 15 2024 16:33 JST
 
More Press release >>

Latest Press Release


More Latest Release >>